Tilray Inc (NASDAQ:TLRY – Get Free Report) fell 2.1% during trading on Tuesday . The company traded as low as $1.17 and last traded at $1.18. 9,745,797 shares traded hands during trading, a decline of 77% from the average session volume of 41,694,473 shares. The stock had previously closed at $1.20.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on TLRY. Roth Mkm dropped their price target on Tilray from $2.00 to $1.75 and set a “neutral” rating on the stock in a research report on Friday, October 11th. Canaccord Genuity Group lifted their target price on Tilray from $2.00 to $3.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $2.70.
Get Our Latest Stock Analysis on Tilray
Tilray Stock Performance
Tilray (NASDAQ:TLRY – Get Free Report) last posted its quarterly earnings results on Friday, January 10th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.07). Tilray had a negative net margin of 30.95% and a negative return on equity of 4.40%. The company had revenue of $210.90 million during the quarter, compared to the consensus estimate of $216.34 million. The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. On average, equities analysts forecast that Tilray Inc will post -0.2 EPS for the current fiscal year.
Insider Transactions at Tilray
In other Tilray news, CFO Carl A. Merton bought 26,000 shares of Tilray stock in a transaction dated Friday, November 15th. The stock was bought at an average cost of $1.36 per share, for a total transaction of $35,360.00. Following the purchase, the chief financial officer now owns 26,000 shares of the company’s stock, valued at $35,360. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.87% of the stock is currently owned by corporate insiders.
Institutional Trading of Tilray
Institutional investors have recently added to or reduced their stakes in the company. Ferguson Wellman Capital Management Inc. bought a new stake in Tilray in the 3rd quarter valued at $26,000. Ameritas Advisory Services LLC acquired a new position in Tilray in the 4th quarter valued at $32,000. International Assets Investment Management LLC raised its holdings in Tilray by 335.3% in the 3rd quarter. International Assets Investment Management LLC now owns 23,639 shares of the company’s stock valued at $42,000 after acquiring an additional 18,208 shares in the last quarter. Vista Capital Partners Inc. acquired a new position in Tilray in the 3rd quarter valued at $42,000. Finally, Capital Management Associates Inc acquired a new position in Tilray in the 3rd quarter valued at $45,000. 9.35% of the stock is currently owned by institutional investors.
About Tilray
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.
Read More
- Five stocks we like better than Tilray
- Buy P&G Now, Before It Sets A New All-Time High
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- 5 discounted opportunities for dividend growth investors
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- Insider Buying Explained: What Investors Need to Know
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.